"Novo wants Ozempic in the market before generics bring out cheaper versions," one of the sources said, adding the launch could happen within the next three to four weeks
Personalized treatments and the development of drugs targeting specific metabolic pathways should also be prioritized as key directions for future therapies
Physical activity is beneficial for both weight control and overall wellbeing in Crohn's disease
Studies showing that the combined actions of both incretin receptor agonists decrease glucagon secretion suggest that the inhibitory actions of GLP-1R agonism outweigh the stimulatory actions of GIPR agonism
Novo Nordisk says the price cuts aim to improve access and affordability in a healthcare system where high list prices can lead to elevated out-of-pocket costs especially for patients with high-deductible insurance or coinsurance tied to list price
however, this may not have clinical relevance [201,202,203]